Zai Lab Limited
ZLAB
Rank in Stocks
#4645
Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a... Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medical treatments. Their therapeutic portfolio spans oncology, autoimmune conditions, infectious diseases, and neurological disorders. Currently available products in their portfolio include Zejula, a once-daily small-molecule PARP 1/2 inhibitor; Optune, a medical device leveraging tumor treating fields; NUZYRA, an antimicrobial agent for specific acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia; and Qinlock, indicated for gastrointestinal stromal tumors. Beyond its commercial offerings, Zai Lab boasts an extensive pipeline of investigational therapies. These include Odronextamab for various B-cell lymphomas; Repotrectinib, a tyrosine kinase inhibitor targeting ROS1 and TRK pathways in both TKI-naรฏve and pretreated cancer patients; Margetuximab for breast and gastroesophageal cancers; Adagrasib for KRAS-G12C-mutated solid tumors like NSCLC, colorectal, and pancreatic cancers; and Bemarituzumab for gastric and gastroesophageal junction cancers. Further pipeline candidates encompass CLN-081 for EGFR exon 20 insertion NSCLC; Elzovantinib, an orally available multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab, designed to block PD-1 interactions with its ligands; ZL-2309, an orally active and selective CDC7 kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod, aimed at reducing pathogenic immunoglobulin G antibodies; ZL-1102, a human nanobody against interleukin-17A; KarXT for psychiatric and neurological conditions; ZL-2313 and ZL-2314, both investigational EGFR inhibitors targeting specific mutations; and Sulbactam/durlobactam, intended for serious infections caused by Acinetobacter. Established in 2013, Zai Lab Limited maintains its corporate headquarters in Shanghai, China.
Share Price
$26.86
Last synced: 2026-11-09
Market Cap
$3.02B
Change (1 day)
5.42%
Change (1 year)
22.76%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Zai Lab Limited (ZLAB)
Category
Healthcare
Operating Margin for Zai Lab Limited (ZLAB)
Operating Margin as of November 2026 TTM: -58.73%
According to Zai Lab Limited's latest financial reports, its current operating margin (TTM) is -58.73%. At the end of 2025 the company had an operating margin of -49.86%.
Operating Margin history for Zai Lab Limited from 2015 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -58.73% | 17.79% |
| 2025 | -49.86% | -29.49% |
| 2024 | -70.71% | -48.55% |
| 2023 | -137.44% | -26.91% |
| 2022 | -188.04% | -61.24% |
| 2021 | -485.10% | -21.31% |
| 2020 | -616.45% | -60.61% |
| 2019 | -1,564.88% | -98.57% |
| 2018 | -109,514.01% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.66% |
US
|
|
| -149.01% | -97.46% |
US
|
|
| 25.57% | -100.44% |
AU
|
|
| 31.23% | -100.53% |
BE
|
|
| 29.35% | -100.50% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Zai Lab Limited's operating margin
What is Zai Lab Limited's operating margin?
Zai Lab Limited's operating margin is -58.73%, as of Nov 2026.
What was Zai Lab Limited's operating margin in 2025?
In 2025, Zai Lab Limited's operating margin was -49.86%, compared with -70.71% in 2024.
How has Zai Lab Limited's operating margin changed since 2020?
From 2020 to 2025, Zai Lab Limited's operating margin was highest in 2025 (-49.86%) and lowest in 2020 (-616.45%).
How does Zai Lab Limited's operating margin compare with similar companies?
Zai Lab Limited's operating margin (-58.73%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.